Loading
Amylyx Pharmaceuticals, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Firestone Karen, was filed 26 May 2026.
Insider Decl.
242
Thresholds
n/a
Buy Volume
€44M
16 ops. · all time
Sell Volume
€89M
135 ops. · all time
Who traded when
BuySaleGina Mazzariello14 sales
Joshua B. Cohen13 sales
Justin B. Klee13 sales
Camille L. Bedrosian7 sales
James M. Frates7 sales
Firestone Karen2 buys
+2 other insiders
Since the insiders bought
- +106.3%Entry US$14.07 · Close 21 Oct 2026 US$29.03
- +265.9%Entry US$3.78 · Close at T+365 US$13.83
- +337.3%Entry US$2.92 · Close at T+365 US$12.77
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Amylyx Pharmaceuticals, Inc. Strong Buy (bullish), based on 11 analysts. Average price target: US$43.00.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$27.33
Analyst consensus
11 analystsStrong buy
US$20.00Target US$43.00(+57%)US$57.00
Income statement
EBITDA-US$152.8M
Net income-US$144.7M0.0% margin
Valuation
PER (forward)-25.1x
P/Book12.7x
Beta-0.09
Balance sheet & cash
Market capUS$3.4B
Total debtUS$6M
Free Cash Flow-US$123.5M
Debt / Equity2%
Profitability & ownership
ROE-74.7%
ROA-44.1%
% insiders7.2%
% institutions92.5%
Last declaration on 7 October 2026
Declarations242 total
30,000 shares@ US$27.69680.024% mcap31.1% of flowCommon StockSEC:0001193125-26-416950:0
100,000 shares@ US$27.790.080% mcap100.0% of flowCommonSEC144:0001950047-26-010033
1,042 shares@ US$33.23020.0010% mcap1.2% of flowCommon StockSEC:0001193125-26-390509:1
7,947 shares@ US$32.21390.0072% mcap22.7% of flowCommon StockSEC:0001193125-26-390510:0
2,081 shares@ US$33.09190.0019% mcap6.1% of flowCommon StockSEC:0001193125-26-390510:1
29,025 shares@ US$32.12930.026% mcap8.6% of flowCommon StockSEC:0001193125-26-390506:0
1,439 shares@ US$33.15520.0013% mcap0.4% of flowCommon StockSEC:0001193125-26-390506:1
29,545 shares@ US$32.15570.027% mcap8.8% of flowCommon StockSEC:0001193125-26-390507:0
919 shares@ US$33.14880.0009% mcap0.3% of flowCommon StockSEC:0001193125-26-390507:1
9,525 shares@ US$32.45560.0087% mcap14.8% of flowCommon StockSEC:0001193125-26-390508:0
11 shares@ US$33.340.0000% mcap0.0% of flowCommon StockSEC:0001193125-26-390508:1
9,768 shares@ US$32.26810.0089% mcap6.5% of flowCommon StockSEC:0001193125-26-390509:0
30,464 shares@ US$32.18570.028% mcap9.1% of flowCommonSEC144:0001193125-26-389243
9,536 shares@ US$32.45660.0087% mcap14.8% of flowCommonSEC144:0001193125-26-389244
10,028 shares@ US$32.39610.0091% mcap28.8% of flowCommonSEC144:0001193125-26-389245
10,810 shares@ US$32.36090.0098% mcap100.0% of flowCommonSEC144:0001193125-26-389246
30,464 shares@ US$32.17780.028% mcap9.0% of flowCommonSEC144:0001193125-26-389247
21,284 shares0Common StockSEC:0001193125-26-359677:0
60,039 shares0Common StockSEC:0001193125-26-359678:0
60,039 shares0Common StockSEC:0001193125-26-359675:0
22,807 shares0Common StockSEC:0001193125-26-359676:0
22,807 shares0Common StockSEC:0001193125-26-359679:0
15,000 shares@ US$18.31640.0071% mcap13.4% of flowCommon StockSEC:0001193125-26-301996:0
15,000 shares@ US$17.60810.0068% mcap12.8% of flowCommon StockSEC:0001193125-26-301996:1
30,000 shares@ US$17.880.014% mcap100.0% of flowCommonSEC144:0001950047-26-006982
25 of 242 declarations
About Amylyx Pharmaceuticals, Inc.
From January 6 to January 11, 2022, 6 insiders of Amylyx Pharmaceuticals bought for EUR 43,715,249, around the stock market listing: EUR 38,568,747 for Viking Global Investors LP (10% Owner) and EUR 4,412,902 for Morningside Venture Investments Ltd (10% Owner) on January 11, 2022, EUR 441,937 for George M. Milne Jr. (Director) on January 6. In all, 16 purchases worth EUR 44.4 million (median EUR 88,607), against 135 sales worth EUR 89.2 million (median EUR 105,726): 11% of open-market trades are purchases. The 16 purchases tracked to day 90 have a stored median of -4.9%, positive in 50% of cases (past results as stored, not a forecast).
Viking Global Investors LP also filed the three largest sales, on September 8 and September 9, 2022: EUR 9,318,070, EUR 4,828,327 and EUR 4,628,869.
Read moreShow less
Joshua B. Cohen (Co-Chief Executive Officer) has 34 filings, 20 of them sales; Justin B. Klee (Co-Chief Executive Officer) 33, James M. Frates (Chief Financial Officer) 31, Gina Mazzariello (Chief Legal Officer) 29 and Morningside Venture Investments Ltd 21, with 17 sales. 242 filings from 23 filers, including 39 grants and 24 option exercises. 2023 is the busiest year, with 76 filings. Last twelve months: 55 filings, 2 purchases, 31 sales. Health care and pharma, USD 3.4 billion, 7.2% held by insiders.
